Historical Press Releases

Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments

Princeton, NJ – August 10, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the second...

Soligenix Announces Positive Phase 1B Clinical Results with RiVaxTM, its Vaccine Against Ricin Toxin Exposure

Princeton, NJ August 30, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial...

Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders

Princeton, NJ – September 13, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company announced today that the US Patent Office granted...

FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohn’s Disease

Princeton, NJ – November 8, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its program for development of...

Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments

Princeton, NJ – November 14, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the third...